Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vespyr Brands
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Equivir is in a placebo-controlled clinical trial for upper respiratory tract infections due to complete Q4 2024; BE-Smart Esophageal Pre-Cancer Diagnostics expected for LDT commercialization in Q3 2025
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculeDiagnostics
- Industry
- Biotech
02
Partnerships
ProPhase Labs (manufacturing agreements and extended partnerships)
Beyond the preview
Go deeper on Vespyr Brands.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vespyr Brands.